UCLA Health13.10.2025
Glioblastoma / Brain TumourPress
UCLA: dendritic cell vaccine in development for rare G34 brain-tumour mutation
UCLA reports on a young patient with a rare G34-mutated brain tumour. During treatment, tumour tissue was preserved that may be used for possible participation in a dendritic cell vaccine study developed by UCLA. The report illustrates how precise tumour characterisation and individualised immunotherapy can be combined.
Context: Development/study context; no evidence of effectiveness for routine care.
Open original source ↗
PubMed2025
GlioblastomStudy
Phase 2 study of personalised dendritic cell vaccines in newly diagnosed glioblastoma
A Phase 2 study published in 2025 investigated personalised dendritic cell vaccines in newly diagnosed glioblastoma. Tumour tissue was obtained during surgery and used for patient-specific vaccine manufacturing. The study provides current clinical data on a personalised DC approach.
Context: Single-arm Phase 2 study; results must be interpreted within the study design.
Open original source ↗
UTHealth Houston / McGovern Medical School2023–2024
GlioblastomPress
UTHealth Houston investigates Th1 dendritic-cell immunotherapy in addition to standard treatment
UTHealth Houston describes a first-in-human pilot study evaluating a personalised Th1 dendritic cell vaccine after surgery and standard chemoradiation in adults with glioblastoma. The primary focus is safety and feasibility.
Context: Early clinical study; preliminary data.
Open original source ↗
Mayo Clinic13.06.2020
GlioblastomPress
Mayo Clinic: new immunotherapy approaches for glioblastoma
Mayo Clinic presents immunotherapy research approaches for glioblastoma and describes, among other things, a dendritic cell vaccine evaluated in an early clinical study in newly diagnosed patients.
Context: Research report from a university clinic.
Open original source ↗
ecancer24.11.2022
GlioblastomPress
DCVax-L: report on survival data in newly diagnosed and recurrent glioblastoma
ecancer summarises a study published in JAMA Oncology on an autologous tumour-lysate-loaded dendritic cell vaccine in glioblastoma. Survival data and a favourable safety profile are reported.
Context: The study used external comparator data; its conclusions should be assessed accordingly.
Open original source ↗
Journal of Clinical Oncology2024
Pancreatic CancerStudy
Dendritic Cell–Based Immunotherapy after surgery for pancreatic cancer
The JCO study investigated dendritic-cell-based immunotherapy in patients with resected pancreatic cancer after completion of standard treatment. It reports, among other outcomes, vaccine-specific immune responses and clinical follow-up data.
Context: Clinical study; results are not transferable to all pancreatic cancers.
Open original source ↗
Nature Communications28.11.2025
Pancreatic CancerStudy
REACtiVe-2: dendritic cell vaccine plus CD40 agonist after FOLFIRINOX
In the Phase I REACtiVe-2 study, patients with metastatic pancreatic adenocarcinoma received an autologous dendritic cell vaccine together with a CD40 agonist after (m)FOLFIRINOX. The primary objectives were safety and tolerability.
Context: Phase I with a small number of patients; primarily a safety study.
Open original source ↗
Frontiers in Immunology2025
Pancreatic CancerStudy
Neoantigen-pulsed dendritic cell vaccine after surgery for pancreatic cancer
The publication describes a neoantigen-based DC vaccine approach after surgical treatment of pancreatic cancer. It focuses on feasibility, immune response and clinical observations within a personalised concept.
Context: Early clinical evidence; further controlled studies are required.
Open original source ↗
Targeted Oncology16.07.2024
Pancreatic CancerPress
FDA Fast Track for DOC1021 in pancreatic adenocarcinoma
Targeted Oncology reports on FDA Fast Track designation for the dendritic cell vaccine DOC1021 in pancreatic adenocarcinoma. Fast Track designation is intended to accelerate development and review.
Context: Fast Track is not an approval and is not proof of effectiveness.
Open original source ↗
Mayo Clinic News Network19.09.2023
Ovarian CancerPress
Mayo Clinic: dendritic cell vaccine for recurrent ovarian cancer
Mayo Clinic describes a research programme in which dendritic cells are produced from patients’ blood and used as a therapeutic vaccine. The current approach investigates a Th17-oriented immune response and combinations with checkpoint inhibition.
Context: Clinical research; no statement about individual treatment success.
Open original source ↗
National Cancer Institute (NCI)2023
Ovarian CancerStudy Registry
FRα dendritic cell vaccine plus pembrolizumab in recurrent ovarian cancer
The NCI is conducting a clinical study evaluating a folate receptor-alpha-targeted dendritic cell vaccine together with pembrolizumab in recurrent ovarian, fallopian-tube or primary peritoneal cancers.
Context: Clinical-trial registry; status and inclusion criteria may change.
Open original source ↗
NCI Center for Cancer Research09.07.2024
Endometrial CancerPress
Combination immunotherapy with a dendritic cell vaccine in endometrial cancer
The NCI Center for Cancer Research reports on a clinical trial of a combination of drug and vaccine therapy in selected HER2-expressing endometrial cancers. Dendritic cell vaccines are part of the investigational concept.
Context: Clinical trial in a selected patient population.
Open original source ↗
National Cancer Institute (NCI)2024
Breast CancerStudy Registry
Personalised DC1 vaccine in high-risk triple-negative breast cancer
An early Phase I study is investigating the manufacturing and safety of a personalised DC1 vaccine in patients with high-risk triple-negative breast cancer and residual disease after chemotherapy and surgery.
Context: Early Phase I study; focus on feasibility and safety.
Open original source ↗
National Cancer Institute (NCI)2024
Breast CancerStudy Registry
DC1 vaccine plus elacestrant in ESR1-mutated metastatic breast cancer
The NCI lists a Phase I study investigating a dendritic cell vaccine tailored to ESR1 mutations together with elacestrant in HR-positive, HER2-negative metastatic breast cancer.
Context: Phase I; experimental combination concept.
Open original source ↗
National Cancer Institute (NCI)2023
Breast CancerStudy Registry
HER2/HER3 dendritic cell vaccine in leptomeningeal metastasis of breast cancer
A Phase I study is investigating HER2/HER3-directed dendritic cell vaccines in patients with breast cancer and leptomeningeal metastasis. Administration takes place within a specialised study protocol.
Context: Highly specific study population; not equivalent to standard DCT.
Open original source ↗
National Cancer Institute (NCI)2025
Multiple MyelomaStudy Registry
DC/MM fusion vaccine plus elranatamab in relapsed multiple myeloma
The NCI describes a study investigating an individualised fusion of dendritic cells and myeloma cells together with elranatamab in relapsed or refractory multiple myeloma.
Context: Experimental study concept; safety and tolerability are being evaluated.
Open original source ↗
National Cancer Institute (NCI)2023
AngiosarcomaStudy Registry
TH1 dendritic-cell vaccine in cutaneous angiosarcoma
A Phase I study is investigating a TH1 dendritic cell vaccine manufactured from patient blood and tumour material in cutaneous angiosarcoma. The concept uses mRNA and lysate loading.
Context: Phase I; rare tumour type and small study population.
Open original source ↗
ecancer08/2026
MelanomaPress
New data on a dendritic cell vaccine in advanced melanoma
ecancer reports current clinical data on a patient-specific dendritic cell vaccine in advanced melanoma. The report describes the vaccine as a therapeutic approach in which DCs convey tumour information to T and B cells.
Context: Current press report; the original study and study design should be reviewed separately.
Open original source ↗
Memorial Sloan Kettering Cancer Center15.07.2024
FandamentalsPress
MSK: dendritic cell, killer T cell and helper T cell form an effective immune triad
MSK reports research suggesting that a spatial triad of a dendritic cell, cytotoxic T cell and helper T cell may be important for an effective anti-tumour response. The findings may have implications for immunotherapies and cancer vaccines.
Context: Basic/translational research; no clinical evidence of DCT effectiveness.
Open original source ↗
Johns Hopkins Medicine28.06.2023
FandamentalsPress
Johns Hopkins: nanoparticles aim to deliver mRNA more specifically to dendritic cells
Johns Hopkins describes a nanoparticle platform intended to deliver mRNA more specifically into dendritic cells. The goal is to improve antigen presentation and thereby activation of tumour-specific T-cell responses for therapeutic cancer vaccines.
Context: Preclinical/technological research.
Open original source ↗
